|RxNews Recap for Monday 12-14-09|
|By Mary Davila|
|Monday, 14 December 2009 19:08|
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
AcuMedSpa Holdings, Inc. (PINKSHEETS:AMSZ) has retired the 220,500,000 shares back to the Transfer Agent, Guardian Registrar and Transfer leaving the outstanding shares at 127,124,965.
Array BioPharma Inc. (NASDAQ: ARRY) today announced positive interim results of its novel, small molecule HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients.
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced the presentation of updated clinical data from its Phase 2 study evaluating oral ridaforolimus in combination with trastuzumab (Herceptin®) in patients with resistant, metastatic breast cancer.
Array BioPharma Inc. (NASDAQ: ARRY) and Amgen Inc.(NASDAQ: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the Company would soon become a fully reporting company.
Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, issued a news release today that disclosed the closing of a private placement fund-raising round.
The Board of Directors of Baxter International Inc. (NYSE:BAX) today elected two new corporate officers of the company.
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it has scheduled its pre-recorded webcast audio conference for Monday, December 21, 2009.
Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced that it has completed the sale of Xenogen Biosciences Corporation ("XenBio"), a subsidiary which provides in-vivo pre-clinical CRO services, to Taconic Farms, Inc. for approximately $11 million.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers.
ChemGenex Pharmaceuticals Limited (ASX:CXS) and Hospira, Inc. (NYSE:HSP) announced today that they have entered into an exclusive agreement to license, develop and commercialize ChemGenex’s product candidate omacetaxine mepesuccinate, a novel targeted cytotoxic pharmaceutical product, in Europe, the Middle East and parts of Africa (the Territory).
Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, and BG Medicine, Inc. (BGM), a Waltham, Massachusetts-based life sciences company, announced today a supply agreement whereby Corgenix will manufacture BGM Galectin-3 diagnostic products in enzyme-linked immunosorbent assay (ELISA) microtiter format exclusively for BG Medicine.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.
Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced today that it has extended its collaboration with The Scripps Research Institute ("Scripps") by entering into an agreement with Scripps to re-annotate the genome of Dyadic's patented and proprietary C1 fungus ("C1").
Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND® (aprepitant) for the treatment of cancer chemotherapy-induced nausea and vomiting.
NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT® technology, today announced the closing of its acquisition of Bio-Quant, Inc., privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
Pfizer Inc. (NYSE: PFE) today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
The board of directors of Pfizer Inc. (NYSE: PFE) today declared an 18-cent first-quarter 2010 dividend on the company’s common stock, payable March 2, 2010, to shareholders of record at the close of business on February 5, 2010.
Seattle Genetics, Inc. (NASDAQ:SGEN), announced its management will host a teleconference at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) on Tuesday, December 15, 2009, to discuss brentuximab vedotin (SGN-35) partnering.
Teva Pharmaceutical Industries, Ltd. (NASDAQ: TEVA) today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions.